Compare Gilead Sciences, Inc. (GILD) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $150.31 (market cap $182.40B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.65 (market cap $168.50B). The key difference: Gilead Sciences, Inc. and Vanguard Emerging Markets Stock Index Fund ETF are close in size by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| GILD | VWO | |
|---|---|---|
Market Cap | $182.40B | $168.50B |
Volume | 4,469,821 | 9,650,999 |
Sector | Health | — |
52-Week High | $155.80 | $61.44 |
52-Week Low | $116.74 | $52.42 |
Typical Hold Time | 111 Days | 134 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
VWO trades at $59.77, down 0.13% on the day, with a bearish technical signal from moving averages and key indicators like ADX signaling selling pressure. Recent news highlights a divergence in performance, with AI-driven strength in Taiwan holdings like TSMC offset by economic weakness in China. The ETF's focus on over 6,000 emerging-market stocks provides diversification but faces concentration risks.
The outlook is cautious due to mixed technicals and regional economic headwinds, particularly in China. Opportunities exist from AI infrastructure growth, but risks include currency volatility and reliance on a few key markets. Investors should weigh the ETF's low expense ratio against emerging-market volatility and slowing growth in major constituents.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
